Fig. 3. Mean arterial plasma concentration-time profiles of tofacitinib after (A) 1-min intravenous infusion (10 mg/kg) into control (CON, n=6), loganin (LGN, n=6), acute kidney injury (AKI, n=7) and acute kidney injury-loganin (AKI-LGN, n=6) rats, and (B) oral administration (20 mg/kg) to CON (n=5), LGN (n=5), AKI (n=6) and AKI-LGN (n=7) rats. Bar represent standard deviations.
© Biomolecules & Therapeutics
